1. Home
  2. ARDX vs PVLA Comparison

ARDX vs PVLA Comparison

Compare ARDX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$6.06

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$117.43

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDX
PVLA
Founded
2007
2015
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ARDX
PVLA
Price
$6.06
$117.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
15
Target Price
$15.14
$171.87
AVG Volume (30 Days)
4.1M
175.2K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,607,000.00
N/A
Revenue This Year
$37.75
N/A
Revenue Next Year
$34.24
$104,350.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.54
$20.20
52 Week High
$8.40
$151.18

Technical Indicators

Market Signals
Indicator
ARDX
PVLA
Relative Strength Index (RSI) 42.92 47.54
Support Level $5.93 $109.68
Resistance Level $6.23 $135.23
Average True Range (ATR) 0.26 5.65
MACD -0.05 0.03
Stochastic Oscillator 0.62 57.12

Price Performance

Historical Comparison
ARDX
PVLA

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Share on Social Networks: